Cargando…

Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo

PURPOSE: We tested the potential of bone morphogenic protein 7 (BMP7) and hepatocyte growth factor (HGF) combination gene therapy to treat preformed corneal fibrosis using established rabbit in vivo and human in vitro models. METHODS: Eighteen New Zealand White rabbits were used. Corneal fibrosis wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Suneel, Fink, Michael K., Ghosh, Arkasubhra, Tripathi, Ratnakar, Sinha, Prashant R., Sharma, Ajay, Hesemann, Nathan P., Chaurasia, Shyam S., Giuliano, Elizabeth A., Mohan, Rajiv R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822743/
https://www.ncbi.nlm.nih.gov/pubmed/29490341
http://dx.doi.org/10.1167/iovs.17-23308
_version_ 1783301744313237504
author Gupta, Suneel
Fink, Michael K.
Ghosh, Arkasubhra
Tripathi, Ratnakar
Sinha, Prashant R.
Sharma, Ajay
Hesemann, Nathan P.
Chaurasia, Shyam S.
Giuliano, Elizabeth A.
Mohan, Rajiv R.
author_facet Gupta, Suneel
Fink, Michael K.
Ghosh, Arkasubhra
Tripathi, Ratnakar
Sinha, Prashant R.
Sharma, Ajay
Hesemann, Nathan P.
Chaurasia, Shyam S.
Giuliano, Elizabeth A.
Mohan, Rajiv R.
author_sort Gupta, Suneel
collection PubMed
description PURPOSE: We tested the potential of bone morphogenic protein 7 (BMP7) and hepatocyte growth factor (HGF) combination gene therapy to treat preformed corneal fibrosis using established rabbit in vivo and human in vitro models. METHODS: Eighteen New Zealand White rabbits were used. Corneal fibrosis was produced by alkali injury. Twenty-four hours after scar formation, cornea received topically either balanced salt solution (BSS; n = 6), polyethylenimine-conjugated gold nanoparticle (PEI2-GNP)-naked plasmid (n = 6) or PEI2-GNP plasmids expressing BMP7 and HGF genes (n = 6). Donor human corneas were used to obtain primary human corneal fibroblasts and myofibroblasts for mechanistic studies. Gene therapy effects on corneal fibrosis and ocular safety were evaluated by slit-lamp microscope, stereo microscopes, quantitative real-time PCR, immunofluorescence, TUNEL, modified MacDonald-Shadduck scoring system, and Draize tests. RESULTS: PEI2-GNP–mediated BMP7+HGF gene therapy significantly decreased corneal fibrosis in live rabbits in vivo (Fantes scale was 0.6 in BMP7+HGF-treated eyes compared to 3.3 in −therapy group; P < 0.001). Corneas that received BMP7+HGF demonstrated significantly reduced mRNA levels of profibrotic genes: α-SMA (3.2-fold; P < 0.01), fibronectin (2.3-fold, P < 0.01), collagen I (2.1-fold, P < 0.01), collagen III (1.6-fold, P < 0.01), and collagen IV (1.9-fold, P < 0.01) compared to the −therapy corneas. Furthermore, BMP7+HGF-treated corneas showed significantly fewer myofibroblasts compared to the −therapy controls (83%; P < 0.001). The PEI2-GNP introduced >10(4) gene copies per microgram DNA of BMP7 and HGF genes. The recombinant HGF rendered apoptosis in corneal myofibroblasts but not in fibroblasts. Localized topical BMP7+HGF therapy showed no ocular toxicity. CONCLUSIONS: Localized topical BMP7+HGF gene therapy treats corneal fibrosis and restores transparency in vivo mitigating excessive healing and rendering selective apoptosis in myofibroblasts.
format Online
Article
Text
id pubmed-5822743
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-58227432018-02-23 Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo Gupta, Suneel Fink, Michael K. Ghosh, Arkasubhra Tripathi, Ratnakar Sinha, Prashant R. Sharma, Ajay Hesemann, Nathan P. Chaurasia, Shyam S. Giuliano, Elizabeth A. Mohan, Rajiv R. Invest Ophthalmol Vis Sci Cornea PURPOSE: We tested the potential of bone morphogenic protein 7 (BMP7) and hepatocyte growth factor (HGF) combination gene therapy to treat preformed corneal fibrosis using established rabbit in vivo and human in vitro models. METHODS: Eighteen New Zealand White rabbits were used. Corneal fibrosis was produced by alkali injury. Twenty-four hours after scar formation, cornea received topically either balanced salt solution (BSS; n = 6), polyethylenimine-conjugated gold nanoparticle (PEI2-GNP)-naked plasmid (n = 6) or PEI2-GNP plasmids expressing BMP7 and HGF genes (n = 6). Donor human corneas were used to obtain primary human corneal fibroblasts and myofibroblasts for mechanistic studies. Gene therapy effects on corneal fibrosis and ocular safety were evaluated by slit-lamp microscope, stereo microscopes, quantitative real-time PCR, immunofluorescence, TUNEL, modified MacDonald-Shadduck scoring system, and Draize tests. RESULTS: PEI2-GNP–mediated BMP7+HGF gene therapy significantly decreased corneal fibrosis in live rabbits in vivo (Fantes scale was 0.6 in BMP7+HGF-treated eyes compared to 3.3 in −therapy group; P < 0.001). Corneas that received BMP7+HGF demonstrated significantly reduced mRNA levels of profibrotic genes: α-SMA (3.2-fold; P < 0.01), fibronectin (2.3-fold, P < 0.01), collagen I (2.1-fold, P < 0.01), collagen III (1.6-fold, P < 0.01), and collagen IV (1.9-fold, P < 0.01) compared to the −therapy corneas. Furthermore, BMP7+HGF-treated corneas showed significantly fewer myofibroblasts compared to the −therapy controls (83%; P < 0.001). The PEI2-GNP introduced >10(4) gene copies per microgram DNA of BMP7 and HGF genes. The recombinant HGF rendered apoptosis in corneal myofibroblasts but not in fibroblasts. Localized topical BMP7+HGF therapy showed no ocular toxicity. CONCLUSIONS: Localized topical BMP7+HGF gene therapy treats corneal fibrosis and restores transparency in vivo mitigating excessive healing and rendering selective apoptosis in myofibroblasts. The Association for Research in Vision and Ophthalmology 2018-02 /pmc/articles/PMC5822743/ /pubmed/29490341 http://dx.doi.org/10.1167/iovs.17-23308 Text en Copyright 2018 The Authors http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Cornea
Gupta, Suneel
Fink, Michael K.
Ghosh, Arkasubhra
Tripathi, Ratnakar
Sinha, Prashant R.
Sharma, Ajay
Hesemann, Nathan P.
Chaurasia, Shyam S.
Giuliano, Elizabeth A.
Mohan, Rajiv R.
Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo
title Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo
title_full Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo
title_fullStr Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo
title_full_unstemmed Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo
title_short Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo
title_sort novel combination bmp7 and hgf gene therapy instigates selective myofibroblast apoptosis and reduces corneal haze in vivo
topic Cornea
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822743/
https://www.ncbi.nlm.nih.gov/pubmed/29490341
http://dx.doi.org/10.1167/iovs.17-23308
work_keys_str_mv AT guptasuneel novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT finkmichaelk novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT ghosharkasubhra novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT tripathiratnakar novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT sinhaprashantr novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT sharmaajay novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT hesemannnathanp novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT chaurasiashyams novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT giulianoelizabetha novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo
AT mohanrajivr novelcombinationbmp7andhgfgenetherapyinstigatesselectivemyofibroblastapoptosisandreducescornealhazeinvivo